BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 32852531)

  • 21. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
    Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
    BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    Zamarin D; Burger RA; Sill MW; Powell DJ; Lankes HA; Feldman MD; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann AR; Khleif S; Aghajanian C
    J Clin Oncol; 2020 Jun; 38(16):1814-1823. PubMed ID: 32275468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carrol BT; Theuner J; Li S; Fu P; Kirkwood JM
    JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
    Buckley HL; Collinson FJ; Ainsworth G; Poad H; Flanagan L; Katona E; Howard HC; Murden G; Banks RE; Brown J; Velikova G; Waddell T; Fife K; Nathan PD; Larkin J; Powles T; Brown SR; Vasudev NS
    BMC Cancer; 2019 Nov; 19(1):1102. PubMed ID: 31727024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
    Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
    Hanna GJ; O'Neill A; Shin KY; Wong K; Jo VY; Quinn CT; Cutler JM; Flynn M; Lizotte PH; Annino DJ; Goguen LA; Kass JI; Rettig EM; Sethi RKV; Lorch JH; Schoenfeld JD; Margalit DN; Tishler RB; Everett PC; Desai AM; Cavanaugh ME; Paweletz CP; Egloff AM; Uppaluri R; Haddad RI
    Clin Cancer Res; 2022 Feb; 28(3):468-478. PubMed ID: 34667025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
    Melero I; Yau T; Kang YK; Kim TY; Santoro A; Sangro B; Kudo M; Hou MM; Matilla A; Tovoli F; Knox J; He AR; El-Rayes B; Acosta-Rivera M; Lim HY; Soleymani S; Yao J; Neely J; Tschaika M; Hsu C; El-Khoueiry AB
    Ann Oncol; 2024 Jun; 35(6):537-548. PubMed ID: 38844309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
    Johnson JM; Vathiotis IA; Harshyne LA; Ali A; Bar Ad V; Axelrod R; Lorber E; Curry J; Cognetti DM; Luginbuhl AJ; Tuluc M; Keith S; Mahoney MG; Argiris A
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
    Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
    Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
    Haddad RI; Harrington K; Tahara M; Ferris RL; Gillison M; Fayette J; Daste A; Koralewski P; Zurawski B; Taberna M; Saba NF; Mak M; Kawecki A; Girotto G; Alvarez Avitia MA; Even C; Toledo JGR; Guminski A; Müller-Richter U; Kiyota N; Roberts M; Khan TA; Miller-Moslin K; Wei L; Argiris A
    J Clin Oncol; 2023 Apr; 41(12):2166-2180. PubMed ID: 36473143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
    N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
    Andresen NK; Røssevold AH; Quaghebeur C; Gilje B; Boge B; Gombos A; Falk RS; Mathiesen RR; Julsrud L; Garred Ø; Russnes HG; Lereim RR; Chauhan SK; Lingjærde OC; Dunn C; Naume B; Kyte JA
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
    Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
    Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
    Hanna GJ; Villa A; Nandi SP; Shi R; ONeill A; Liu M; Quinn CT; Treister NS; Sroussi HY; Vacharotayangul P; Goguen LA; Annino DJ; Rettig EM; Jo VY; Wong KS; Lizotte P; Paweletz CP; Uppaluri R; Haddad RI; Cohen EEW; Alexandrov LB; William WN; Lippman SM; Woo SB
    JAMA Oncol; 2024 Jan; 10(1):32-41. PubMed ID: 37971722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
    Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
    Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.